A Biomarker for the Early Detection of Severe Sepsis

A novel diagnostic biomarker for the quick differentiation between severe sepsis and systematic inflammatory response syndrome (SIRS), allowing the proper treatment to begin sooner than with current methods.

 

Problem Solved by the Technology
Severe sepsis is the leading cause of death in non-coronary ICUs, affecting 750,000 individuals in the United States annually with ~30% mortality rate. Current diagnostic procedures are based on detection of pathogens in the blood, resulting in a delayed diagnosis 2-3 days later. Clinical early identification and management remain a challenge since there is a correlation between early sepsis intervention and survival rates. In addition, the ability to differentiate sepsis from SIRS can help match patients with the right treatment.

 

Applications
Researchers from University of Rochester have shown in human samples that neutrophils VLA-3 expression levels are correlated to the severity of sepsis and can be used clinically to differentiate sepsis from SIRS. The VLA-3 biomarker can be measured using standard immunodiagnostic techniques with the preferred methods of rapid test formats. Unlike current diagnostic methods, the use of the novel biomarker VLA-3 provides prompt results. Also, the ability to differentiate between sepsis and SIRS quickly allows for the best suited therapy to be selected for critically ill patients.

URV Reference Number: 6-2196
Patent Information:
Category(s):
Diagnostic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Minsoo Kim
Keywords: